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A Comprehensive Analysis Reveals Mutational
Spectra and Common Alleles in Chinese Patients with
Oculocutaneous Albinism
Aihua Wei1,2,4, Yu Wang2,4, Yan Long3,4, Yi Wang1,4, Xiaoli Guo1, Zhiyong Zhou1, Wei Zhu2, Juntao Liu3,
Xuming Bian3, Shi Lian2 and Wei Li1
Oculocutaneous albinism (OCA) is a heterogeneous recessive disorder with hypopigmentation in the skin, hair,
and eyes. At least 16 genes have been identified as causative genes for human OCA. No comprehensive analysis
has been conducted to study the spectral distribution of OCA in Chinese patients. We screened 127 unrelated
and unselected Chinese OCA patients for mutations in the TYR, OCA2, TYRP1, SLC45A2, and HPS1 genes. We
found that the spectrum of mutational genes and alleles of OCA is population specific. OCA1 is the most
common (70.1% of cases) form of Chinese OCA, whereas OCA2, OCA4, and HPS1 account for 10.2%, 12.6%, and
1.6%, respectively. No apparent pathological mutation of TYRP1 has been found. Thirty-eight previously
unreported mutational alleles were identified from these OCA patients and were not found in 100 nonalbinism
subjects. Of the TYR mutational alleles, 81.1% were clustered on exons 1 and 2. Ten common alleles account for
74.6% of the mutational TYR alleles in Chinese OCA1 patients. The p.D160H allele accounts for 55.6% of the
mutational SLC45A2 alleles in Chinese OCA4 patients. These results provide useful information for the
establishment of an optimized strategy of gene diagnosis and genetic counseling of Chinese OCA patients.
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INTRODUCTION
Oculocutaneous albinism (OCA) is regarded as an inherited
trait, with a reduction or complete absence of melanin in the
skin, hair, and eyes. It is often accompanied by eye problems,
including photophobia, strabismus, moderate to severe
impairment of visual acuity, and nystagmus. OCA is a
heterogeneous and autosomal recessive disorder. At least
16 genes have been identified as causative for OCA in
humans (Tomita and Suzuki, 2004; Li et al., 2006). These
include four types of nonsyndromic OCA genes (TYR/OCA1,
P/OCA2, TYRP1/OCA3, and MATP/SLC45A2/OCA4) and 12
syndromic OCA genes (HPS1, AP3B1/HPS2, HPS3, HPS4,
HPS5, HPS6, DTNBP1/HPS7, HPS8, LYST/CHS1, MYO5A/
GS1, RAB27A/GS2, and MLPH/GS3). Although RAB38, SILV,
and SLC24A5 are suggestive of candidate OCA genes, no
pathological mutations have been reported in human OCA
patients (Suzuki et al., 2003; Hutton and Spritz, 2008a;
Grønskov et al., 2009). More candidate OCA genes in
humans are likely to be identified as implicated by additional
mouse OCA genes (Bennett and Lamoreux, 2003; Li et al.,
2004). Patients with autosomal recessive ocular albinism,
which has been ruled out as stemming from mutations in the
GPR143/OA1 gene, have been found with mutations in the
TYR or OCA2 genes, which are considered clinically mild
variants of OCA1 and OCA2 (Hutton and Spritz, 2008b).
The prevalence of OCA subtypes differs widely among
different populations. Among African and African-American
OCA patients, OCA2 is the most frequent form (King et al.,
2001).OCA1 has been reported to be the most frequent type
of OCA in Japanese (Suzuki and Tomita, 2008), non-Hispanic
Caucasians (Hutton and Spritz, 2008a), Danes (Grønskov
et al., 2009), and a mixed population of Europeans, Asians,
and Africans (Rooryck et al., 2008). Similarly, the mutational
spectrum of each OCA gene varies in different populations
(Suzuki and Tomita, 2008; Hutton and Spritz, 2008a;
Grønskov et al., 2009). In the Chinese Han population of
Shangdong Province, the prevalence of OCA was reported to
be 1:18,000. It is estimated that at least eight genes contribute
to recessive OCA, and 3.83% of the general population of
Shangdong Province are carriers (Gong et al., 1994). Thus, a
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large number of individuals with OCA would be expected
to be born annually in such a huge population (1.3 billion).
Mutational screenings have been conducted in a small
number of Chinese OCA patients, and several previously
unreported mutational alleles of TYR, OCA2, and SLC45A2
have been identified in the Chinese population (Li et al.,
2006, 2008; Wang et al., 2009a). However, no comprehen-
sive molecular analysis has been conducted to reveal the
spectral distribution of Chinese OCA. In this study, 127 OCA
patients from the Chinese Han population, the largest
population in China, were recruited for extensive mutational
screening of TYR, OCA2, TYRP1, SLC45A2, and HPS1.
RESULTS
OCA1 is the most common type of OCA in Chinese patients
Of the 127 OCA patients, 74 were clinically diagnosed with
OCA1, 35 were diagnosed with OCA2, and 18 were not
differentially diagnosed because of unclear onset history
(Table 1).Of these patients, 94.5% (120 of 127) were
confirmed by molecular testing, with the remaining 5.5%
(7 of 127) unidentified after mutational screening of the TYR,
OCA2, TYRP1, SLC45A2, and HPS1 genes. Of the 120
molecularly diagnosed patients, 99 carried two mutational
alleles and 21 carried one mutational allele. Of the identified
patients, we found apparent pathological TYR mutations in
70.1% of the patients (89 of 127), OCA2 mutations in 10.2%
(13 of 127), SLC45A2 mutations in 12.6% (16 of 127), and
HPS1 mutations in 1.6% (2 of 127) (Table 1). No mutation
in TYRP1 was found in these patients. Hence, OCA1 is the
predominant type of OCA in the Chinese Han population.
Allelic frequencies of TYR in Chinese OCA patients
Of the 89 OCA1 patients, 80 had two mutational alleles and
9 had one mutational allele in the TYR gene (Table 1). Forty-
three mutational alleles were identified (Table 2 and Figure 1).
Fifteen of these have not previously been reported (Table 1):
p.C24R, p.W39C, p.W39R, p.R77G, p.C100F, p.C100W,
p.M185V, p.H211R, p.R212T, p.Y235H, p.W236R,
p.D249G, c.1146C4G (p.N382K), p.A481E, and p.G506X.
In addition to these previously unreported TYR mutational
alleles, 12 alleles reported in other populations (p.H19R,
p.G41R, p.R77W, p.R299C, c.1037-7T4Aþ -10delTT,
p.H390D, p.R402G, p.R402X, p.H404P, p.G419R,
p.R422Q, and c.1314delCTTT) are reported here in Chinese
patients for the first time. Different alleles lead to different
changes at the same residue, such as p.C24R/Y, p.R77G/Q/
W, and p.C100F/W. Similarly, different alleles may result in
the same missense mutation; for example, both c.1146C4A
(Tripathi et al., 1992) and c.1146C4G (this study) lead to the
same N382K mutation. The c.1037-10delTT allele cosegre-
gates with c.1037-7T4A (Spritz, 1993) in all five of our
patients with these alleles. It is worth noting that the
previously reported mutational allele c.1217C4T (p.P406L),
as shown in patient 18 (Table 1), was identified as an allele
from a pseudogene, TYRL (Chaki et al., 2005b). Interestingly,
c.575C4A (p.S192Y), as found in patient 77 (Table 1), has
been reported as a single-nucleotide polymorphism (SNP),
rs1042602, in several populations, including Caucasians,
Africans, Japanese, and South Asians. However, in the
Chinese Han population, the frequency of allele C is 1.00 in
the National Center for Biotechnology Information
SNP database (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.
cgi?rs=rs1042602). Similarly, we did not find the A allele in
any of the 100 unaffected subjects from the Han population.
The C allele is associated with darker skin (Stokowski et al.,
2007). It is uncertain whether the c.575C4A allele con-
tributes to the development of OCA symptoms in a double
heterozygous state with other mutational alleles in the Han
population.
Among these TYR alleles, p.R299H and c.929insC
account for 15.4% (26 of 169) and 14.8% (25 of 169),
respectively. p.R278X ranks third, with 11.8% (20 of 169).
Other alleles with higher frequencies are c.232insGGG
(5.9%, 10 of 169), W400L (5.9%, 10 of 169), R116X (5.3%,
9 of 169), C24Y (4.1%, 7 of 169), C55Y (4.1%, 7 of 169),
R77Q (4.1%, 7 of 169), and c.1037-7T4Aþ -10delTT (3.0%,
5 of 169). The above 10 alleles account for 74.6% (126 of
169) of the mutational TYR alleles in the Chinese OCA
patients in our study. The remaining 33 alleles were found in
one or two copies in these patients (Table 2).
Allelic frequencies of OCA2, SLC45A2, and HPS1 in Chinese
OCA patients
Of the 13 OCA2 patients, 7 had two mutational alleles and 6
had one mutational allele in the OCA2 gene. Of the 16
mutational alleles, 2 were known mutations (p.P198L and
p.L727P), and the remaining 14 were previously unreported
mutational alleles (c.168delC, c.980insT, c.860_883del24bp,
c.2351_2376del26 bp, p.R136X, p.K155N, p.R243C,
p.Q321P, p.C430X, p.T450K, p.R455G, p.R555C,
p.A776D, and p.G782R) (Table 1). The most frequent allele
in this screen was p.R455G, which accounts for 15% (3 of 20)
of the mutational OCA2 alleles.
Of the 16 OCA4 patients, 11 had two mutational alleles
and 5 had one mutational allele in the SLC45A2 gene. Of 27
mutational alleles, 11 different alleles were detected (Table 1).
All but two—p.D157N and p.D160H (Inagaki et al., 2004;
Li et al., 2008)—are previously unreported mutations:
c.-5_5delTGGCCATGGG, c.463delG, p.G110R, p.L151P,
p.H233Q, p.Y266X, p.G349R, p.E368K, and p.P419L. The
most common allele was p.D160H, with an allelic frequency
of 55.6% (15 of 27). The p.D160H heterozygotes or
homozygotes were clinically diagnosed as either OCA1A or
OCA2 (Table 1) on the basis of hair pigmentation.
Finally, a homozygous c.1932delC mutation in HPS1 was
found in a clinically diagnosed OCA1 patient—the first
molecularly identified Hermansky–Pudlak syndrome type 1
(HPS1) patient (Wei et al., 2009). In addition, a heterozygous
known mutation, c.965insC, which has been reported in
Caucasians (Oh et al., 1998), was found in patient 120, who
has clinically diagnosed OCA2 (Table 1). This patient was a
5-year-old girl with brown hair, white skin, dark brown irises,
remarkable nystagmus, and photophobia. She had no bruises
in her lower legs, and all coagulation tests, including
activated partial thromboplastin time, prothrombin and
thrombin times, and fibrinogen, were within normal ranges.
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Table 1. Gene mutations in 127 Chinese OCA patients
Patient no. Sex
Clinical
diagnosis
Molecular
diagnosis Mutation 1 Mutation 2
OCA1/TYR
1 M OCA1B OCA1A c.832C4T(p.R278X) c.832C4T(p.R278X)
2 M OCA1B OCA1B c.117G4T(p.W39C)* c.164G4A(p.C55Y)
3 M OCA1A OCA1A c.232insGGG c.1199G4T(p.W400L)
4 M OCA1A OCA1A c.896G4A(p.R299H) c.70T4C(p.C24R)*
5 F OCA1A OCA1A c.832C4T(p.R278X) c.1211A4C(p.H404P)
6 M OCA1A OCA1A c.896G4A(p.R299H) c.1199G4T(p.W400L)
7 M OCA1B OCA1A c.232insGGG c.1147G4A(p.D383N)
8 F OCA1B OCA1B c.232insGGG c.1204C4G(p.R402G)
9 F OCA1A OCA1A c.929insC c.832C4T(p.R278X)
10 F OCA1A OCA1A c.230G4A(p.R77Q) c.929insC
11 M OCA1A OCA1A c.346C4T(p.R116X) c.832C4T(p.R278X)
12 M OCA1A OCA1A c.896G4A(p.R299H) c.896G4A(p.R299H)
13 M OCA1A OCA1A c.832C4T(p.R278X) c.1211A4C(p.H404P)
14 M OCA1A OCA1A c.929insC c.895C4T(p.R299C)
15 F OCA1A OCA1A c.346C4T(p.R116X) c.1425G4A(p.W475X)
16 M OCA1A OCA1A c.346C4T(p.R116X) c.346C4T(p.R116X)
17 F OCA1A OCA1A c.706T4C(p.W236R)* c.832C4T(p.R278X)
18 F OCA1A OCA1B c.896G4A(p.R299H) c.1217C4A(p.P406L)@
19 M OCA1A OCA1A c.230G4A(p.R77Q) c.929insC
20 F OCA1A OCA1A c.117G4T(p.W39C) c.896G4A(p.R299H)
21 F OCA1A OCA1A c.232insGGG c.1199G4T(p.W400L)
22 F OCA1A OCA1A c.56A4G(p.H19R) c.896G4A(p.R299H)
23 M OCA1A OCA1A c.896G4A(p.R299H) c.896G4A(p.R299H)
24 M OCA1A OCA1A c.346C4T(p.R116X) c.929insC
25 F OCA1A OCA1A c.232insGGG c.896G4A(p.R299H)
26 M OCA2 OCA1B c.164G4A(p.C55Y) c.553A4G(p.M185V)*
27 F OCA1B OCA1A c.758G4A(p.G253E) c.929insC
28 M OCA2 OCA1A c.832C4T(p.R278X) c.929insC
29 M OCA1A OCA1A c.929insC c.1146C4G(p.N382K)*
30 F OCA2 OCA1B c.229C4G(p.R77G)* c.1146C4G(p.N382K)
31 F OCA1A OCA1A c.703T4C(p.Y235H)* c.632A4G(p.H211R)*
32 F OCA2 OCA1B c.832C4T(p.R278X) c.1037-7T4A+-10delTT
33 M OCA1A OCA1A c.929insC c.1199G4T(p.W400L)
34 M OCA2 OCA1B c.896G4A(p.R299H) c.1037-7T4A+-10delTT
35 M OCA1A OCA1A c.1199G4T(p.W400L) c.1314delCTTT
36 M OCA2 OCA1B c.71G4A(p.C24Y) c.1199G4T(p.W400L)
37 M OCA1A OCA1A c.896G4A(p.R299H) c.832C4T(p.R278X)
38 F OCA1A OCA1A c.832C4T(p.R278X) c.1199G4T(p.W400L)
39 M OCA1A OCA1A c.832C4T(p.R278X) c.929insC
40 F OCA1A OCA1A c.71G4A(p.C24Y) c.164G4A(p.C55Y)
41 M OCA1A OCA1A c.164G4A(p.C55Y) c.346C4T(p.R116X)
42 M OCA1A OCA1A c.71G4A(p.C24Y) c.232insGGG
43 M OCA1B OCA1B c.1348insGG c.1199G4T(p.W400L)
44 F OCA1A OCA1A c.929insC c.929insC
Table 1 continued on the following page
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Table 1. Continued
Patient no. Sex
Clinical
diagnosis
Molecular
diagnosis Mutation 1 Mutation 2
45 M OCA1A OCA1A c.832C4T(p.R278X) c.929insC
46 M OCA1A OCA1A c.71G4A(p.C24Y) c.346C4T(p.R116X)
47 M OCA1A OCA1A c.896G4A(p.R299H) c.929insC
48 M OCA1B OCA1B c.820-3C4G c.832C4T(p.R278X)
49 M OCA1A OCA1A c.832C4T(p.R278X) c.895C4A(p.R299S)
50 F OCA1A OCA1A c.71G4A(p.C24Y) c.230G4A(p.R77Q)
51 M OCA1A OCA1A c.346C4T(p.R116X) c.346C4T(p.R116X)
52 M OCA1B OCA1B c.425A4T(p.K142M) c.896G4A(p.R299H)
53 M OCA1A OCA1A c.896G4A(p.R299H) c.896G4A(p.R299H)
54 F OCA1A OCA1A c.929insC c.896G4A(p.R299H)
55 F OCA OCA1B c.230G4A(p.R77Q) c.229C4T(p.R77W)
56 F OCA OCA1 c.121G4A(p.G41R) c.299G4T(p.C100F)*
57 F OCA OCA1A c.832C4T(p.R278X) c.164G4A(p.C55Y)
58 F OCA OCA1A c.929insC c.232insGGG
59 M OCA1A OCA1B c.1037-7T4A+-10delTT c.896G4A(p.R299H)
60 F OCA1A OCA1A c.703T4C(p.Y235H) c.820-3C4G
61 F OCA OCA1B c.929insC c.1199G4T(p.W400L)
62 F OCA OCA1 c.1516C4T(p.G506X)* c.895C4T(p.R299C)
63 F OCA1A OCA1A c.929insC c.1168C4G(p.H390D)
64 F OCA1A OCA1A c.230G4A(p.R77Q) c.71G4A(p.C24Y)
65 F OCA OCA1A c.896G4A(p.R299H) c.832C4T(p.R278X)
66 M OCA1A OCA1A c.164G4A(p.C55Y) c.635G4C(p.R212T)*
67 F OCA OCA1A c.896G4A(p.R299H) c.929insC
68 M OCA1A OCA1A c.300T4G(p.C100W)* c.896G4A(p.R299H)
69 F OCA OCA1 c.929insC c.1348insGG
70 F OCA OCA1A c.232insGGG c.832C4T(p.R278X)
71 F OCA OCA1A c.896G4A(p.R299H) c.896G4A(p.R299H)
72 F OCA2 OCA1B c.1265G4A(p.R422Q) c.929insC
73 F OCA1A OCA1A c.832C4T(p.R278X) c.896G4A(p.R299H)
74 M OCA2 OCA1B c.1255G4A(p.G419R) c.1037-7T4A+-10delTT
75 M OCA1A OCA1A c.896G4A(p.R299H) c.230G4A(p.R77Q)
76 M OCA2 OCA1B c.1265G4A(p.R422Q) c.115T4C(p.W39R)*
77 F OCA2 OCA1B c.929insC c.575C4A(p.S192Y)#
78 F OCA1B OCA1A c.929insC c.1199G4T(p.W400L)
79 F OCA1A OCA1A c.232insGGG c.1204C4T(p.R402X)
80 M OCA1A OCA1A c.746A4G(p.D249G)* c.758G4A(p.G253E)
81 F OCA1A OCA1A c.896G4A(p.R299H) c.929insC
82 M OCA1A OCA1A c.929insC c.832C4T(p.R278X)
83 F OCA OCA1B c.895C4A(p.R299S) —
84 M OCA1A OCA1 c.230G4A(p.R77Q) —
85 M OCA2 OCA1B c.1037-7T4A+-10delTT —
86 M OCA1A OCA1 c.232insGGG —
87 F OCA1A OCA1 c.71G4A(p.C24Y) —
88 F OCA1B OCA1 c.1442C4A(p.A481E)* —
89 F OCA OCA1 c.164G4A(p.C55Y) —
Table 1 continued on the following page
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Table 1. Continued
Patient no. Sex
Clinical
diagnosis
Molecular
diagnosis Mutation 1 Mutation 2
OCA2/P
90 M OCA2 OCA2 c.2327C4A(p.A776D)* c.465G4T(p.K155N)*
91 F OCA2 OCA2 c.2344G4A(p.G782R)* c.980insT*
92 F OCA2 OCA2 c.1349C4A(p.T450K)* c.2180T4C(p.L727P)
93 F OCA2 OCA2 c.168delC* c.727C4T(p.R243C)*
94 F OCA2 OCA2 c.593C4T(p.P198L) c.593C4T(p.P198L)
95 M OCA1A OCA2 c.860_883del24 bp* c.2351_2376del26 bp*
96 M OCA1A OCA2 c.1363A4G(p.R455G)* c.1290T4A(p.C430X)*
97 M OCA OCA2 c.727C4T(p.R243C) —
98 M OCA2 OCA2 c.406C4T(p.R136X)* —
99 M OCA2 OCA2 c.1363A4G(p.R455G) —
100 M OCA2 OCA2 c.962A4C(p.Q321P)* —
101 M OCA2 OCA2 c.1663C4T(p.R555C)* —
102 F OCA OCA2 c.1363A4G(p.R455G) —
OCA4/SLC45A2
103 M OCA2 OCA4 c.478G4C(p.D160H) c.1045G4A(p.G349R)*
104 F OCA2 OCA4 c.478G4C(p.D160H) c.478G4C(p.D160H)
105 F OCA2 OCA4 c.463delG* c.463delG
106 M OCA1A OCA4 c.478G4C(p.D160H) c.478G4C(p.D160H)
107 F OCA2 OCA4 c.478G4C(p.D160H) c.478G4C(p.D160H)
108 F OCA OCA4 c.478G4C(p.D160H) c.478G4C(p.D160H)
109 F OCA2 OCA4 c.452T4C(p.L151P)* c.798C4G(p.Y266X)*
110 M OCA1A OCA4 c.469G4A(p.D157N) c.328G4A(p.G110R)*
111 M OCA1A OCA4 c.478G4C(p.D160H) c.1256C4T(p.P419L)*
112 M OCA2 OCA4 c.1102G4A(p.E368K)* c.478G4C(p.D160H)
113 M OCA2 OCA4 c.478G4C(p.D160H) c.478G4C(p.D160H)
114 M OCA2 OCA4 c.699T4A(p.H233Q)* —
115 M OCA2 OCA4 c.478G4C(p.D160H) —
116 F OCA2 OCA4 c.-5_5delTGGCCATGGG* —
117 M OCA2 OCA4 c.328G4A(p.G110R) —
118 F OCA2 OCA4 c.478G4C(p.D160H) —
HPS1
119 F OCA1 HPS1 c.1932delC c.1932delC
120 F OCA2 HPS1 c.965insC —
Unknown
121 M OCA ? — —
122 M OCA1 ? — —
123 M OCA1A ? — —
124 F OCA2 ? — —
125 F OCA2 ? — —
126 F OCA ? — —
127 M OCA2 ? — —
OCA, oculocutaneous albinism.
*Represents previously unknown alleles.
A dash (—) in the mutation column denotes an uncharacterized allelic mutation.
#Indicates a very rare SNP in this population.
@Represents a nonpathological allele amplified from the pseudogene TYRL.
? Denotes uncharacterized genotype.
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Her platelet count was also within the normal range, but the
result of an ADP (adenosine diphosphate)-induced platelet
aggregation test was 73% (normal range 20–60%).
Hotspots of TYR in Chinese OCA patients
In OCA1, 28 of 43 mutational alleles are located on exons 1
and 2 of the TYR gene, accounting for 81.1% (137 of 169) of
the total mutational alleles. In particular, four alleles account-
ing for nearly half of the TYRmutations (45.6%, 77 of 169) are
located on exon 2 and close to the splicing acceptor of intron 1
(Figure 1). This suggests that exons 1 and 2 are the hotspots of
TYR mutations in the Chinese Han population.
In OCA4, the p.D160H allele accounts for more than half
of the mutational SLC45A2 alleles, suggesting a founder
mutational allele in the Chinese Han population, which is
close to another founder allele (p.D157N) among Japanese
and Koreans (Inagaki et al., 2005). In OCA2, the current
reported mutations are sparsely distributed in the entire gene,
without apparent mutation hotspots in the Chinese Han
population. In the HPS1 gene, a frameshift hotspot at codons
321–322 is apparent in non–Puerto Rican individuals (Oh
et al., 1998). This study is the first to report the c.965insC
mutation at this site in a Chinese HPS1 patient.
DISCUSSION
The distribution of disease genes and mutational alleles of a
specific gene may vary in different populations. OCA shows
this variation within populations. The prevalences of TYR,
OCA2, SLC45A2, and HPS1 are 70.1, 10.2, 12.6, and 1.6%,
respectively, in the Chinese population, which are different
from those in other populations such as Japanese (Suzuki and
Tomita, 2008), non-Hispanic Caucasians (Hutton and Spritz,
2008a), and Danes (Grønskov et al., 2009). However, TYR
is the most common OCA gene in these four populations,
whereas OCA2 is the most frequent form in African and
African-American OCA patients (King et al., 2001). Similar
to non-Hispanic Caucasians (Hutton and Spritz, 2008a), no
mutation in TYRP1was found in our OCA repository. However,
10% of Japanese OCA patients have mutations in HPS1 (Suzuki
and Tomita, 2008), but a lower frequency of HPS1 (1.6%) in
Chinese OCA patients was reported here, which is attributable
to the population-specific spectrum. When molecular testing is
conducted in a more comprehensive manner and in more OCA
patients, some rare type of OCA or HPS would be expected in
Chinese patients. Nevertheless, unidentified OCA patients
will provide an important resource for screening potential,
previously unreported OCA genes in this repository.
Table 2. Allelic frequencies of the TYR gene in 89 Chinese OCA1 patients
Location Allele
No. of
chromosomes Location Allele
No. of
chromosomes
Exon 1 p.H19R 1 Intron 1 c.820-3C4G 2
p.C24Y 7 Exon 2 p.R278X 20
p.C24R 1 p.R299H 26
p.W39C 2 p.R299C 2
p.W39R 1 p.R299S 2
p.G41R 1 c.929insC 25
p.C55Y 7 Intron 2 c.1037-7T4A+-10delTT 5
p.R77Q 7 Exon 3 p.N382K 2
p.R77G 1 p.D383N 1
p.R77W 1 p.H390D 1
c.232insGGG 10 Exon 4 p.W400L 10
p.C100F 1 p.R402G 1
p.C100W 1 p.R402X 1
p.R116X 9 p.H404P 2
p.K142M 1 p.G419R 1
p.M185V 1 p.R422Q 2
p.H211R 1 c.1314delCTTT 1
p.R212T 1 c.1348insGG 2
p.Y235H 2 p.W475X 1
p.W236R 1 Exon 5 p.A481E 1
p.D249G 1 p.G506X 1
p.G253E 2 Total 169
OCA, oculocutaneous albinism.
Of the 89 OCA1 patients, two mutational alleles were identified in 80, and one mutational allele was identified in 9.
www.jidonline.org 721
A Wei et al.
Mutational Spectrum of Chinese OCA Patients
The origin of the mutational alleles of these OCA genes
may provide useful information for evolutionary studies of the
populations. Interestingly, the p.R299H mutation of TYR
ranks as the most frequent allele in Chinese (Table 2),
Caucasians (Tripathi et al., 1992), Koreans (Park et al., 1997),
and Christian Arabs (Zahed et al., 2005), suggesting that it
is a common mutational allele in human OCA1. Both the
c.929insC and p.R278X alleles in TYR have been reported in
some Asian populations (Tripathi et al., 1993; Park et al.,
1997; Tomita, 2000; Chaki et al., 2005a). Several mutations
of TYR with higher allelic frequencies, such as p.W400L (Lin
et al., 2006), c.232insGGG (Tsai et al., 1999), and p.C24Y
(Wang et al., 2009a), have to date been reported only in
Chinese OCA patients. Another mutation, p.D160H, is the
most common allele of SLC45A2 in Chinese OCA4 patients.
The mutational spectrum of each OCA gene was found to
vary in different populations when a comprehensive analysis
was conducted in a larger number of cases. This is evident
in Japanese (Suzuki and Tomita, 2008), non-Hispanic
Caucasians (Hutton and Spritz, 2008a), and Danes (Grønskov
et al., 2009). In Caucasians, TYR mutations are clustered in
exons 1 and 4 (King et al., 1991; Tripathi et al., 1992). In this
study, we found that exons 1 and 2 are the mutational
hotspots of the TYR gene in the Chinese Han population.
These mutational hotspots will be used when designing
diagnostic methods in this population.
We did not find the second mutation in 19 patients, after
sequencing all the exons and the adjacent exon–intron
boundaries of the genes containing the first mutational allele.
The percentage of unidentified alleles is similar to that
observed in other studies (King et al., 2003; Rooryck et al.,
2008; Hutton and Spritz, 2008a; Grønskov et al., 2009).
Those ‘‘uncharacterized mutations’’ have been suggested to
be located upstream of the gene within locus control-like
regions, or, alternatively, the mutation may be present at a
second locus (digenic scenario) (Passmore et al., 1999; King
et al., 2003; Ray et al., 2007; Hutton and Spritz, 2008b). The
uncharacterized mutations from the missing gross deletions
or insertions were possibly due to amplification of the
existing wild-type allele in a regular genomic PCR. In our
study, although attempts to screen large deletional mutations
on TYR or SLC45A2 were made, no deletions were found
(data not shown). Other possibilities of uncharacterized
mutations include mutations in unsequenced intronic regions
that result in functional changes of proteins.
On the basis of the spectrum of mutational genes and
common alleles, we recommend screening for mutations in
TYR, SLC45A2, OCA2, and HPS1 sequentially for genetic
diagnosis of OCA in the Chinese Han population and
prioritizing the sequencing of hotspots in exons 1 and 2 of
TYR and in exon 2 of SLC45A2. In fact, using our optimized
screening strategy, we have reached a much higher success
rate (94.5%) in molecular diagnosis of OCA. In addition, we
have identified the missed second mutational allele in three
patients reported previously (Wang et al., 2009a) in this
extensive screening.
In summary, we have described the prevalence of various
OCA-causative genes in a Chinese Han population. The
mutational spectrum of each OCA gene is different from that
found in other populations, and possible mutational hotspots
have been described in the TYR gene in this population. The
genotype–phenotype correlations suggest that molecular
diagnosis is more accurate in the differentiation of OCA
subtypes. These findings will be useful for gene diagnosis and
genetic counseling of OCA in China.
MATERIALS AND METHODS
Study subjects
We recruited 127 unrelated OCA patients and 100 unaffected
subjects from the Chinese Han population for a phase II study
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Figure 1. Distribution of mutational alleles of the TYR gene in the Chinese Han population. Boxes represent five different exons as indicated, and solid lines
connecting these boxes represent the introns of the TYR gene. The numbers above the boxes indicate the positions of the TYR complementary DNA at the
start–stop sites and exon–intron boundaries. Vertical lines represent the locations of the mutational alleles of missense (above the boxes) or nonsense/frameshift/
splicing (below the boxes) mutations. The numbers under the brackets denote the total allelic frequencies of the alleles included.
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(Table 1). The patients in the Chinese Albinism Registry were from
more than 20 provinces of China (He and Li, 2007). Only two OCA
patients (nos. 44 and 105) had a family history of consanguinity. The
14 OCA1 patients who were described previously (Wang et al.,
2009a) were included in this study for extensive molecular analysis
and for the calculation of spectral distribution. Typically, among
clinically diagnosed OCA1 patients, OCA1A presents with white
hair that does not change with age and OCA1B is characterized by
white hair at birth that later becomes light yellow or darker (Oetting
et al., 2003). OCA2 is characterized by yellow, brown, or golden
hair at birth that may darken at a later age. Owing to unclear onset
history or too young an age, some patients were not clinically
differentially diagnosed; they are listed as OCA or OCA1 in the
‘‘Clinical diagnosis’’ column of Table 1. In all 127 OCA patients,
white skin, blue or brown irises, and mild to severe nystagmus were
observed. This study was approved by the internal review board of
the bioethics committees of the Institute of Genetics and Develop-
ment Biology, Chinese Academy of Sciences, and Xuanwu Hospital,
Capital Medical University, and Union Hospital, Peking Union
College. The study was conducted according to the Declaration of
Helsinki Principles. Written informed consent was obtained and 8ml
peripheral blood samples were collected from all subjects partici-
pating in this study.
Genomic amplifications from whole-blood samples
Total genomic DNA was extracted from blood samples using the
routine proteinase K/SDS method. Standard PCR amplification
procedures were used with an annealing temperature of 58–59 1C
for all primers. Primer sequences are available on request. The
amplifications cover all the exons and exon–intron boundaries of the
five OCA genes: TYR, OCA2, TYRP1, SLC45A2, and HPS1.
Optimized strategy for mutational screening
Single-strand conformation polymorphism analysis was used for the
first round of mutational screening of TYR, OCA2, and SLC45A2.
When shifted bands of the polymorphisms were repeated twice,
or when no shifted bands were observed, the PCR products were
subjected to direct sequencing. When a potentially previously
unreported mutation was considered after a careful check with the
Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/), the
Hermansky–Pudlak Syndrome Database (http://liweilab.genetics.
ac.cn/HPSD/), and the SNP database (http://www.ncbi.nlm.nih.
gov/SNP/), denaturing high-performance liquid chromatography
analysis or direct sequencing was used to test the 100 unaffected
subjects to exclude the possibility of polymorphism. The procedures
for single-strand conformation polymorphism and denaturing high-
performance liquid chromatography were described in more detail
for the mutational screening of the GPR143 gene (Wang et al.,
2009b). For direct sequencing, all purified PCR products were
sequenced using the ABI PRISM 3700 automated sequencer
(Applied Biosystems, Foster City, CA).
For all the OCA patients, mutations on the TYR gene were
first screened. When no mutation in the TYR gene was found, the
SLC45A2 and OCA2 genes were screened sequentially for clinically
diagnosed OCA1 patients, and OCA2 and SLC45A2 were screened
sequentially for clinically diagnosed OCA2 patients. When no point
mutation was found on TYR and SLC45A2, a set of combinational
primers was applied to screen deletional mutations. When mutations
on TYR, OCA2, and SLC45A2 were not found after the above efforts,
TYRP1 and HPS1 were screened sequentially by direct sequencing.
When blood samples were collected from a patient’s parents,
paternal and maternal origins of the mutational alleles were verified
to exclude de novo germline mutations and to identify biallelism or
triallelism.
Development of a web-based tool for mutation conversion
During mutational screening, when a nucleotide change in cDNA is
spotted, the identification of the functional consequence at the
protein level is labor intensive, involving a manual check of the
mutational position and the genetic codes. Here, we developed a
user-friendly Web-based tool, MutConv, for mutation conversion
from cDNA to protein by following the guidelines of mutation
nomenclature (den Dunnen and Antonarakis, 2000).
The MutConv tool (http://liweilab.genetics.ac.cn/MutConv/) was
developed with Perl, running as Apache CGI at the back end and
designed with HTML, CSS, and Javascript for the front end. The
reference cDNA sequence is put into a box in MutConv. The cDNA
mutation is described in a separate box following the rules of
mutation description for substitution, insertion, and deletion (http://
www.hgvs.org/mutnomen/) (den Dunnen and Antonarakis, 2000).
After the program is run, pairwise alignment of the original and
mutated cDNA sequences is displayed, followed by pairwise
alignment of the original and mutated protein sequences. The
mutated base pairs in cDNA or amino acid residues in polypeptide
are highlighted. The output includes a description of the mutation at
the protein level. MutConv was used to verify all the mutations from
cDNA to protein in this study.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We are grateful to the volunteers for donating blood samples, especially
members of the Chinese Network of Albinism (http://www.albinism.org.cn).
We thank Richard T Swank for his invaluable comments and for editing
the manuscript. This work was supported, in part, by the National Natural
Science Foundation of China (30525007 and 30730049), the National Basic
Research Program of China (2006CB504100, 2006CB500700, and
2007CB947200), the Natural Science Foundation of Beijing (7092040), and
the Capital Medical Development Foundation (2007-3111).
REFERENCES
Bennett DC, Lamoreux ML (2003) The color loci of mice—a genetic century.
Pigment Cell Res 16:333–44
Chaki M, Mukhopadhyay A, Chatterjee S, Das M, Samanta S, Ray K (2005a)
Higher prevalence of OCA1 in an ethnic group of eastern India is due to
a founder mutation in the tyrosinase gene. Mol Vis 11:531–4
Chaki M, Mukhopadhyay A, Ray K (2005b) Determination of variants in the
30-region of the tyrosinase gene requires locus specific amplification.
Hum Mutat 26:53–8
den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and
suggestions to describe complex mutations: a discussion. Hum Mutat
15:7–12
Gong Y, Shao C, Zheng H, Chen B, Guo Y (1994) Study on genetic
epidemiology of albinism. Yi Chuan Xue Bao 21:169–72
Grønskov K, Ek J, Sand A, Scheller R, Bygum A, Brixen K et al. (2009) Birth
prevalence and mutation spectrum in Danish patients with autosomal
recessive albinism. Invest Ophthalmol Vis Sci 50:1058–64
www.jidonline.org 723
A Wei et al.
Mutational Spectrum of Chinese OCA Patients
He M, Li W (2007) China genetic counseling network (CGCN): a website on
genetic counseling and genetic education. Hereditas 29:381–4
Hutton SM, Spritz RA (2008a) Comprehensive analysis of oculocutaneous
albinism among non-Hispanic caucasians shows that OCA1 is the most
prevalent OCA type. J Invest Dermatol 128:2442–50
Hutton SM, Spritz RA (2008b) A comprehensive genetic study of autosomal
recessive ocular albinism in Caucasian patients. Invest Ophthalmol Vis
Sci 49:868–72
Inagaki K, Suzuki T, Ito S, Suzuki N, Fukai K, Horiuchi T et al. (2005) OCA4:
evidence for a founder effect for the p.D157N mutation of the MATP
gene in Japanese and Korean. Pigment Cell Res 18:385–8
Inagaki K, Suzuki T, Shimizu H, Ishii N, Umezawa Y, Tada J et al. (2004)
Oculocutaneous albinism type 4 is one of the most common types of
albinism in Japan. Am J Hum Genet 74:466–71
King RA, Hearing VJ, Creel DJ, Oetting WS (2001) Albinism. In: The
Metabolic & Molecular Basis of Inherited Disease (Scriver CR,
Beaudet AL, Valle D, Sly WS, eds). 8th ed. New York: McGraw-Hill,
5587–627
King RA, Mentink MM, Oetting WS (1991) Non-random distribution of
missense mutations within the human tyrosinase gene in type I
(tyrosinase-related) oculocutaneous albinism. Mol Biol Med 8:19–29
King RA, Pietsch J, Fryer JP, Savage S, Brott MJ, Russell-Eggitt I et al. (2003)
Tyrosinase gene mutations in oculocutaneous albinism 1 (OCA1):
definition of the phenotype. Hum Genet 113:502–13
Li H, Meng S, Zheng H, Wei H, Zhang Y (2008) A Chinese case of
oculocutaneous albinism type 4 with two novel mutations. Int J
Dermatol 47:1198–201
Li W, He M, Zhou HL, Bourne JW, Liang P (2006) Mutational data integration
in gene-oriented files of Hermansky–Pudlak syndrome database. Hum
Mutat 27:402–7
Li W, Rusiniak M, Chintala S, Gautum R, Novak EK, Swank RT (2004) Murine
Hermansky–Pudlak syndrome: genes which control lysosome-related
organelles. Bioessays 26:616–28
Lin S, Chien S, Su Y, Lee C, Chen C (2006) Rapid genetic analysis of
oculocutaneous albinism (OCA1) using denaturing high performance
liquid chromatography (DHPLC) system. Prenat Diagn 26:466–70
Oetting WS, Fryer JP, Shriram S, King RA (2003) Oculocutaneous albinism
type 1: the last 100 years. Pigment Cell Res 16:307–11
Oh J, Ho L, Ala-Mello S, Amato D, Armstrong L, Bellucci S et al. (1998)
Mutation analysis of patients with Hermansky–Pudlak syndrome: a
frameshift hot spot in the HPS gene and apparent locus heterogeneity.
Am J Hum Genet 62:593–8
Park S-K, Lee K-H, Park K-C, Lee J-S, Spritz RA, Lee S-T (1997)
Prevalent and novel mutations of the tyrosinase gene in Korean
patients with tyrosinase-deficient oculocutaneous albinism. Mol Cell
7:187–91
Passmore LA, Kaesmann-Kellner B, Weber BH (1999) Novel and recurrent
mutations in the tyrosinase gene and the P gene in the German albino
population. Hum Genet 105:200–10
Ray K, Chaki M, Sengupta M (2007) Tyrosinase and ocular diseases: some
novel thoughts on the molecular basis of oculocutaneous albinism type 1.
Prog Retin Eye Res 26:323–58
Rooryck C, Morice-Picard F, Elc¸ioglu NH, Lacombe D, Taieb A, Arveiler B
(2008) Molecular diagnosis of oculocutaneous albinism: new mutations
in the OCA1-4 genes and practical aspects. Pigment Cell Melanoma Res
21:583–7
Spritz RA (1993) Molecular genetics of oculocutaneous albinism. Semin
Dermatol 12:167–72
Stokowski RP, Pant PVK, Dadd T, Fereday A, Hinds DA, Jarman C et al. (2007)
A genome-wide association study of skin pigmentation in a South Asian
population. Am J Hum Genet 81:1119–32
Suzuki T, Miyamura Y, Inagaki K, Tomita Y (2003) Characterization of the
human RAB38 and RAB7 genes: exclusion of new major pathological
loci for Japanese OCA. J Dermatol Sci 32:131–6
Suzuki T, Tomita Y (2008) Recent advances in genetic analyses of
oculocutaneous albinism types 2 and 4. J Dermatol Sci 51:1–9
Tomita Y (2000) Tyrosinase associated oculocutaneous albinism (OCA1). Jpn J
Dermatol 109:1974–6
Tomita Y, Suzuki T (2004) Genetics of pigmentary disorders. Am J Med Genet
C Semin Med Genet 131C:75–81
Tripathi RK, Bundey S, Musarella MA, Droetto S, Strunk KM, Holmes SA et al.
(1993) Mutations of the tyrosinase gene in Indo-Pakistani patients with
type I (tyrosinase-deficient) oculocutaneous albinism (OCA). Am J Hum
Genet 53:1173–9
Tripathi RK, Strunk KM, Giebel LB, Weleber RG, Spritz RA (1992) Tyrosinase
gene mutations in type I (tyrosinase-deficient) oculocutaneous albinism
define two clusters of missense substitutions. Am J Med Genet 43:865–71
Tsai CH, Tsai FJ, Wu JY, Lin SP, Chang JG, Yang CF et al. (1999) Insertion/
deletion mutations of type I oculocutaneous albinism in Chinese patients
form Taiwan. Hum Mutat 14:542
Wang Y, Guo XL, Li W, Lian S (2009a) Four novel mutations of TYR gene in
Chinese OCA1 patients. J Dermatol Sci 53:80–1
Wang Y, Guo XL, Wei AH, Zhu W, Li W, Lian S (2009b) Identification of a
novel mutation in a Chinese family with X-linked ocular albinism. Eur J
Ophthalmol 19:124–8
Wei AH, Lian S, Wang LJ, Li W (2009) The first case report of a Chinese
Hermansky–Pudlak syndrome patient with a novel mutation on HPS1
gene. J Dermatol Sci 56:130–2.
Zahed L, Zahreddine H, Noureddine B, Rebeiz N, Shakar N, Zalloua P et al.
(2005) Molecular basis of oculocutaneous albinism type 1 in Lebanese
patients. J Hum Genet 50:317–9
724 Journal of Investigative Dermatology (2010), Volume 130
A Wei et al.
Mutational Spectrum of Chinese OCA Patients
